Pharmacokinetics and clinical response to single- and multiple-dose sustained-release theophylline compounds in perennial bronchial asthma

  • C.H. Fanta
    Shipley Institute of Medicine, Harvard Medical School, Boston, Massachusetts, USA
    Search for articles by this author
  • E.R. McFadden Jr.
    Requests for reprints should be addressed to Dr. E. R. McFadden, Jr., Asthma and Allergic Disease Center, University Hospitals, 2074 Abington Road, Cleveland, Ohio 44106.
    Asthma and Allergic Disease Center, and Departments of Medicine, University Hospitals and Case Western Reserve University School of Medicine, Cleveland, Ohio, USA
    Search for articles by this author
      This paper is only available as a PDF. To read, Please Download here.


      Nine adult subjects with perennial bronchial asthma participated in a single-blind, cross-over, placebo-controlled study to evaluate and compare the effectiveness of a 24-hour sustained-release theophylline formulation, Uniphyl, with that of a twice-daily compound, Theo-Dur. The subjects took each drug for two weeks and monitored peak expiratory flow and recorded their symptoms in a diary three times daily. At the end of each experimental period, they were hospitalized for 24 hours for determination of the pharmacokinetics of the compound they were taking and the relationship between fluctuations in theophylline blood levels and changes in pulmonary mechanics. Both drugs were highly effective, and no significant differences between formulations were found in any aspects of the study. The results demonstrate that a single daily dose of Uniphyl is an efficacious form of therapy for controlling perennial asthma in adults.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to The American Journal of Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Salter H
        On some points in the treatment and clinical history of asthma.
        Edinb Med J. 1858; 4: 1109-1115
        • Hendles L
        • Weinberger M
        in: A “state of the art” review. 6th ed. Pharmacotherapy. 3. 1983: 2-44
        • Bundgaard A
        • Weeke B
        Long term treatment with oral sustained-release theophylline.
        Allergy. 1982; 37: 149-154
        • Tabachnik E
        • Scott P
        • MacLeod S
        • et al.
        Sustained release theophylline in treatment of childhood asthma-a significant advance.
        J Pediatr. 1982; 100: 489-492
        • Bell T
        • Bigley J
        Sustained release theophylline therapy for chronic childhood asthma.
        Pediatrics. 1978; 62: 352-358
        • American Thoracic Society
        Definition and classification of chronic bronchitis, asthma, and pulmonary emphysema.
        Am Rev Respir Dis. 1962; 85: 762-768
        • Dechtiaruk WA
        • Johnson GF
        • Solomon HA
        Faster gas-chromatographic procedures for theophylline.
        Clin Chem. 1975; 21: 1038-1039
        • Hendeles L
        • Iafrate RP
        • Weinberger M
        A clinical and pharmacokinetic basis for the selection and use of slow release theophylline products.
        Clin Pharmacokinetics. 1984; 9: 95-135
        • Wagner JG
        Biopharmaceutics and Relevant Pharmacokinetics.
        in: Drug Intelligence Publications, Hamilton, Illinois1971: 278
        • Tinkelman DG
        • Vanderpool GE
        • Carroll MS
        • Page EG
        • Spangler DL
        Compliance differences following administration of theophylline at six and twelve hour intervals.
        Ann Allergy. 1980; 44: 283-286
        • Busse WW
        • Bush RK
        Comparison of morning and evening dosing with a 24-hour sustained-release theophylline, Uniphyl, for nocturnal asthma.
        Am J Med. 1985; 79: 62-66
        • Fairshter RD
        • Bhola R
        • Thomas R
        • Wilson AF
        • et al.
        Comparison of clinical effects and pharmacokinetics of once daily Uniphyl and twice daily Theo-Dur in asthmatic patients.
        Am J Med. 1985; 79: 48-53
        • Fink JN
        • Levy MB
        • Conrad E
        Study of two controlled-release theophylline preparations.
        Am J Med. 1985; 79: 58-61
        • Cohen BM
        Serum profile and bioavailability of a controlled release theophylline formulation for once a day use: comparison with a 12 hour preparation.
        J Asthma. 1984; 21: 305-309
        • Barnes PJ
        • Greening AP
        • Neville L
        • Timmers J
        • Poole GW
        Single-dose slow-release aminophylline at night prevents nocturnal asthma.
        Lancet. 1982; I: 299-301
        • Clark TJH
        • Hetzel MR
        Diurnal variations of asthma.
        Br J Dis Chest. 1977; 71: 87-92
        • Lagas M
        • Jonkman JHG
        Greatly enhanced bioavailability of theophylline on postprandial administration of a sustained release tablet.
        Eur J Clin Pharmacol. 1983; 24: 761-767
        • Leeds NH
        • Gal P
        • Purohit AA
        • Walter JB
        Effect of food on the bioavailability and pattern of release of a sustained-release theophylline tablet.
        J Clin Pharmacol. 1982; 22: 196-200